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Abstract p19INK4d, a member of the INK4 family of cyclin-
dependent kinase (CDK) inhibitors, negatively regulates the
cyclin D^CDK4/6 complexes, which promote G1/S transition by
phosphorylating the retinoblastoma tumor-suppressor gene
product. To investigate the mechanism of transcriptional
regulation of the p19INK4d gene, we characterized the 5P-flanking
region of the human p19INK4d gene. The cap-site hunting method
revealed that the transcription starts at 316 nucleotide (nt)
upstream of the initiation codon. The 5P-flanking region of the
human p19INK4d gene was ligated to a luciferase reporter gene
and possessed functional promoter activity. Luciferase assay with
a series of truncated 5P-flanking regions indicated that the region
from 381 to 32 nt could drive the transcription of the p19INK4d
gene. Several Sp1 and activating protein 2 binding sites are
located within the region from 381 to 32 nt. Mutation of the
second Sp1 binding site from 333 to 325 nt decreased the
promoter activity. Collectively, it was demonstrated that the
human p19INK4d gene is under the control of TATA-less promoter
and the Sp1 binding site is involved in the transcription. ß 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
In the eukaryotic cell cycle, several positive and negative
factors regulate the cell cycle progression. Among the positive
factors, the key molecules are a family of protein kinases each
of which comprises a regulatory subunit, or cyclin, and a
catalytic subunit, termed a cyclin-dependent kinase (CDK).
A number of reports have suggested that cyclin D^CDK4/6
and cyclin E^CDK2 play important roles in promoting the
transition from the G1 phase to the S phase by the phosphor-
ylation of the retinoblastoma protein (pRB). One further level
of control has recently become apparent, namely, the expres-
sion of CDK inhibitors [1]. Two families of CDK inhibitors
have already been identi¢ed in mammalian cells, with di¡erent
modes of action. One group, comprised of related proteins
known as p21Cip1=Waf1, p27Kip1 and p57Kip2, inhibits a broader
spectrum of cyclin/CDK complexes [2^5]. The second family
of CDK inhibitors is also called INK4 family proteins. The
four members of this family, designated p15INK4b, p16INK4a,
p18INK4c and p19INK4d, bind directly to CDK4/6 and are
therefore speci¢c inhibitors of the cyclin D-dependent kinases
[6^8].
The four proteins of the INK4 family possess a similar
structure dominated by several ankyrin repeats and bind to
CDK4/6 with similar a⁄nity, but they are reported to have
di¡erent biological roles. p16INK4a functions as a tumor sup-
pressor. Inactivation of the p16INK4a gene through gene dele-
tions, point mutations or transcriptional silencing by methyl-
ation of the promoter is one of the most frequent defects
contributing to oncogenesis [9^12]. Mice de¢cient in
p16INK4a develop normally and are highly cancer prone
[13,14]. Disruption of p15INK4b does not in£uence develop-
ment of mice, but leads to frequent lymphoproliferative dis-
orders [15]. Mice lacking p18INK4c have deregulated epithelial
cell growth, resulting in the frequent development of various
types of neoplasia [15,16]. p19INK4d-de¢cient mice exhibit
marked testicular atrophy associated with increased apoptosis
of germ cells, suggesting an important role for p19INK4d in
testis development [17].
A possible molecular basis for these biochemically indistin-
guishable molecules to carry out distinct biological functions
appears to lie in di¡erences in the transcriptional regulation.
In fact, the INK4 proteins are expressed in distinct, tissue-
speci¢c patterns [18]. Furthermore, their transcription is
known to respond di¡erentially to diverse stimuli. Induction
of p15INK4b in response to transforming growth factor L, or
upregulation of p16INK4a with increasing population dou-
blings or following some oncogenic stimuli, or increased ex-
pression of p18INK4c associated with the antiproliferative ac-
tion of interleukin-6, are among examples of such di¡erential
transcriptional regulation [11,12,19]. In the present study, to
investigate the mechanism of the transcriptional regulation of
the p19INK4d gene, we cloned the 5P-£anking region of the
human p19INK4d gene and analyzed its promoter region.
2. Materials and methods
2.1. Cell culture
The human T lymphoblastic cell line Jurkat (a kind gift from Dr.
J.I. Fujisawa, Kansai Medical University) was maintained in RPMI
1640 medium with 10% fetal bovine serum and incubated at 37‡C in a
humidi¢ed atmosphere of 5% CO2.
0014-5793 / 02 / $22.00 ß 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 2 6 4 7 - 9
*Corresponding author. Fax: (81)-75-241 0792.
E-mail address: tsakai@basic.kpu-m.ac.jp (T. Sakai).
Abbreviations: AP-2, activating protein 2; SRY, sex determining re-
gion Y
FEBS 26036 12-4-02
FEBS 26036FEBS Letters 517 (2002) 272^276
2.2. Cloning of the 5P-£anking region
Genome screening was performed using a human genomic leuko-
cyte library in the VPS1 phage (Mo Bi Tec, Go«ttingen, Germany).
Phage plaques (1U107) of this library were screened with a 32P-la-
beled probe encoding a part of the human p19INK4d gene. This probe
was ampli¢ed by PCR based on the data in GenBank no. AF044171,
with the forward (5P-AGCTCGTAGTAAGGGCCAATGAATGT-
TCT-3P) and the reverse (5P-ACAAACTCGCTACTGTGTAGCGG-
CA-3P) primers. The positive phage plaques were puri¢ed through
three rounds of rescreening, and the phage DNA was converted to
plasmid DNA by transduction into a Cre-recombinase-expressing bac-
terial strain. The genomic DNA fragments were digested with the
appropriate enzymes and analyzed by Southern blotting.
2.3. Determination of the transcriptional start site
To identify the transcriptional start site, the cap-site hunting meth-
od with human testis cap-site cDNA (Nippon Gene, Toyama, Japan)
was used according to the manufacturer’s instructions. Brie£y, r-oligo
was ligated to the 5P-end of cap-removed mRNA and the linked
mRNA was used to synthesize the ¢rst-stranded cDNA by reverse
transcriptase in the presence of oligo-dT primers. The ¢rst round of
PCR was performed using a sense DNA primer complementary to
r-oligo (1RDT; 5P-GATGCTAGCTGCGAGTCAAGTC-3P) paired
with the target gene-speci¢c antisense primer 3 (TGP3; 5P-GTG-
TCCAGGAATCCAGTGCG-3P ; based on the data in GenBank no.
NM_001800). Aliquots of the ¢rst PCR reaction were used as the
template in the second round of PCR reaction (nested PCR). Nested
PCR was performed using sense DNA primer complementary to
r-oligo (2RDT; 5P-CGAGTCAAGTCGACGAAGTGC-3P) paired
with the nested target gene-speci¢c antisense primers 1 or 2 (TGP1,
5P-GTCTTGCCGAAGCGGTTGAG-3P ; TGP2, 5P-TGCTGCCAA-
ACATCATGACC-3P). The PCR products were cloned into TA vec-
tor and sequenced using a DNA sequencer (Applied Biosystems Inc.).
2.4. Construction of the reporter plasmid
An approximately 3.8 kb fragment derived from the positive phage
DNA was subcloned into luciferase reporter plasmid pGVB2 (Nippon
Gene, Tokyo, Japan). This human p19INK4d-luciferase fusion plasmid
was termed p19 (33814/32). The deletion mutants of p19 (33814/
32), termed p19 (3265/32) and p19 (381/32), were generated using
a Mungbean-Exonuclease III system from the Kilo-sequence Deletion
kit (Takara, Tokyo, Japan). The reporter plasmids with mutations in
the activating protein 2 (AP-2) binding site 375/365 (Mutation 1),
the Sp1 binding site 339/331 (Mutation 2) and the Sp1 binding site
333/325 (Mutation 3) were generated by site-directed mutagenesis
[20] using the Quick Change Site-Directed Mutagenesis kit (Strata-
gene). The top strands of the oligonucleotides were as follows, with
mutations indicated by underlines; Mutation 1, 5P-CGCTAGC-
CATCT-3P ; Mutation 2, 5P-GGGTTTTGG-3P ; Mutation 3, 5P-
GGATGGGTA-3P. All of the generated constructs were con¢rmed
by sequencing.
2.5. Transient transfection and luciferase activity
Reporter constructs were co-transfected with pRL-TK (Promega)
to standardize by Renilla luciferase activity. Jurkat cells (1U106 cells)
were transfected with a total of 5.1 Wg DNA (5 Wg reporter plasmid
and 0.1 Wg pRL-TK) by the DEAE-dextran method [21]. Cells were
harvested 48 h after transfection. The luciferase activity of each cell
lysate was measured using the Dual-Luciferase Reporter Plasmid Sys-
tem (Promega). The ¢re£y luciferase activity of each sample was nor-
malized by its Renilla luciferase activity and the fold activation was
obtained by setting the value of the empty vector control as 1.0. All of
the transfection assays were carried out in triplicate.
3. Results and discussion
3.1. Molecular cloning of human genomic fragment containing
the p19INK4d promoter
To investigate the mechanism of the transcriptional regula-
tion of the p19INK4d gene, we cloned a genomic DNA frag-
ment containing the human p19INK4d promoter region. A part
of the human p19INK4d genomic DNA fragment was obtained
by PCR. Using this probe, 1U107 phage plaques of a human
leukocyte genomic library were screened to obtain the ge-
nomic DNA fragment containing the 5P-£anking region of
Fig. 1. Nucleotide sequence of the 5P-£anking region of the human p19INK4d gene. The transcriptional start site of the human p19INK4d gene
was determined by the cap-site hunting method and is indicated by the arrowhead. The various potential transcriptional factor binding sites are
indicated. The nucleotide number was counted from the ¢rst base of the initiation codon. The arrows indicate the 5P-end of the deletion mu-
tants of the p19INK4d promoters shown in Fig. 3.
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the human p19INK4d gene. Four positive clones were identi¢ed
and phage DNAs were converted to plasmid DNAs by trans-
duction into a Cre-recombinase-expressing bacterial strain.
The plasmid DNAs were digested with several restriction en-
zymes and analyzed by Southern blotting using the same
probe. These fragments contained the 5P-£anking region,
exon 1 and intron 1 of the human p19INK4d gene (data not
shown).
3.2. Sequence analysis of the human p19INK4d promoter
A 3.8 kb fragment containing the 5P-£anking region of the
human p19INK4d gene was subcloned into pGVB2 and se-
quenced. A computer search using MatInspector V2.2 at the
TRANSFAC WWW site [22] for potential regulatory ele-
ments in the promoter region revealed that there could be
multiple transcriptional factor binding sites such as Sp1,
AP-2, CCAAT, sex determining region Y (SRY), GATA-3
and E2F (Fig. 1) which might transcriptionally regulate the
p19INK4d gene expression. Analysis of the region surrounding
the transcriptional start site failed to reveal the presence of a
TATA box.
3.3. Transcriptional start site of the human p19INK4d promoter
To identify the transcriptional start site, the cap-site hunt-
ing method was performed with human testis cap-site cDNA.
In the ¢rst ampli¢cation, no speci¢c PCR products were de-
tectable using 1RDT as the sense primer complementary to
r-oligo and TGP3 as the target gene-speci¢c antisense primer
(data not shown). The resulting cDNA extending to the cap
site was then ampli¢ed by nested PCR in the presence of
2RDT as the sense primer complementary to r-oligo and ei-
ther TGP1 or TGP2 as the target gene-speci¢c antisense prim-
er. The ampli¢ed products were electrophoresed on agarose
gels and stained with ethidium bromide (Fig. 2). Products of
approximately 220 and 250 bp were obtained using 2RDT/
TGP1 and 2RDT/TGP2, respectively. Two speci¢c PCR prod-
ucts were cloned and sequenced. The results of sequencing
analysis demonstrated that all 15 selected clones terminated
at the same nucleotide, 316 nt from the initiation codon (Fig.
1), indicating that this nucleotide is the major transcriptional
start site of the human p19INK4d promoter.
3.4. Promoter activity and deletion analysis of the human
p19INK4d promoter
To analyze the promoter activity of the 5P-£anking region
of the p19INK4d gene, several deletion mutants were generated
by the Mungbean-Exonuclease III system. A series of the 5P-
deletion constructs were subcloned into the luciferase reporter
plasmid pGVB2 and transfected into the human T lympho-
blastic cell line Jurkat. The expression of p19INK4d gene in this
cell line was con¢rmed by Northern blot analysis (data not
shown). The full-size human p19INK4d promoter construct,
p19 (33814/32), conferred luciferase activity six-fold higher
than that of the parental vector (Fig. 3). The deleted con-
structs of p19 (3265/32) and p19 (381/32) showed luciferase
activity three-fold higher than that of the parental vector (Fig.
3). These results suggest that the region between 381 and 32
nt might include the transactivating elements of the human
p19INK4d gene.
Fig. 2. Gel electrophoresis of PCR products of oligo-capped
p19INK4d mRNA. Human testis cap-site cDNA was used as a PCR
template to identify the transcriptional start site of the human
p19INK4d gene. The ¢rst round of PCR was performed using 1RDT
as the sense DNA primer complementary to r-oligo and TGP3 as
the gene-speci¢c antisense primer. An aliquot of the initial PCR re-
action served as the template for nested PCR. The resulting cDNA
extending to the cap site was ampli¢ed by nested PCR using 2RDT
as the nested sense DNA primer complementary to r-oligo and ei-
ther TGP1 or TGP2 as the nested gene-speci¢c antisense primer.
The nested PCR products were electrophoresed on 2% agarose gels
and stained with ethidium bromide. Lane 1, 100 bp DNA ladder
(molecular size marker); lane 2, nested PCR product using 2RDT/
TGP1; lane 3, nested PCR product using 2RDT/TGP2.
Fig. 3. Deletion mutants of the human p19INK4d promoter-luciferase constructs. The human full-size p19INK4d promoter-luciferase construct,
p19 (33814/32), was generated by subcloning a 3.8 kb DNA fragment in front of the luciferase reporter gene in pGVB2. The 5P-deletion mu-
tants were generated using the Mungbean-Exonuclease III system. Jurkat cells were transfected with the di¡erent reporter gene constructs to-
gether with the pRL-TK vector, which served as an internal control. The ¢re£y luciferase activity of each sample has been normalized by its
Renilla luciferase activity, and this value has subsequently been compared with the mean value of the empty pGVB2 to acquire the fold induc-
tion of each construct. Data are shown as means þ S.D. (n = 3).
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3.5. Mutational analysis of the human p19INK4d promoter
Potential binding sites for Sp1 and AP-2 are located in the
region between 381 and 32 nt (Fig. 1). To clarify the con-
tribution of these sites to the transcription, we introduced
mutations in each of these binding sites using the deleted
construct, p19 (381/32). We mutated the AP-2 binding site
at 375/365 (p19mutAP-2), the Sp1 binding site at 339/331
(p19mutSp1-1) and the Sp1 binding site at 333/325
(p19mutSp1-2). The mutations at the AP-2 and Sp1 (339/
331) sites did not a¡ect the promoter activity, but the muta-
tion at the Sp1 (333/325) site signi¢cantly reduced the pro-
moter activity (Fig. 4). These results suggest that the second
Sp1 binding site, 333/325, is involved in the transcription of
the p19INK4d gene.
3.6. Future aspects of transcriptional regulation of the p19INK4d
gene
The results of the present study indicate that the human
p19INK4d gene is under control of TATA-less promoter, and
that the transcription starts at 316 nt upstream of the initia-
tion codon, and that Sp1 binding site at 333/325 is involved
in the transcription. The result of Fig. 3 shows that the pro-
moter activity of the region between 381 and 32 nt is about
half of that of the full-size promoter region (33814/32). Fur-
thermore, mutational analysis in Fig. 4 indicates that the Sp1
(333/325) site is essential for the promoter activity of the
region 381 to 32 nt. Therefore it is considered that the Sp1
(333/325) site contributes to about half of the p19INK4d pro-
moter activity, suggesting the Sp1 (333/325) site as one of the
essential elements of the p19INK4d promoter. Sp1 is ubiqui-
tously expressed in a wide variety of tissues and hence regu-
lates numerous genes including common house keeping genes
[23]. This is consistent with the previous report that p19INK4d
gene is widely expressed in most cell lines and mouse normal
tissues [18,24].
The computer search using MatInspector V2.2 at the
TRANSFAC WWW site [22] for potential regulatory ele-
ments in the promoter region revealed that there could be
multiple transcriptional factor binding sites such as Sp1,
AP-2, CCAAT, SRY, GATA-3 and E2F (Fig. 1) which might
transcriptionally regulate p19INK4d gene expression. In partic-
ular, we had much interest in the E2F binding site. Phosphor-
ylation of pRB by cyclin D^CDK4/6 and cyclin E^CDK2 at
the G1/S phase results in the release of E2F transcriptional
factors, which activate numerous genes associated with G1/S
phase progression. A previous report has shown that the ex-
pression of p19INK4d gene oscillates through the cell cycle,
with the levels of mRNA increasing as cells entered the
S phase [8]. To determine if the p19INK4d gene promoter is
transactivated by E2F, transient transfections were performed
by co-transfecting the E2F1 e¡ector plasmid with the full-
size human p19INK4d promoter construct, p19 (33814/32).
However, E2F1 did not signi¢cantly alter the luciferase
activity (data not shown). This result suggests that the
E2F binding site in the p19INK4d promoter might not be func-
tional.
The p19INK4d gene is controlled by a post-translational
mechanism such as ubiquitination [25]. However, several re-
ports have shown an increase of p19INK4d mRNA induced by
several cytokines and neuronal di¡erentiation, suggesting that
the p19INK4d gene is also transcriptionally regulated in some
cases [26^31]. Our present work of molecular cloning and
characterization of the p19INK4d gene promoter may provide
a powerful means for investigating the regulatory mechanism
of these diverse stimuli.
Inactivation of p16INK4a has been extensively reported in
almost all human cancer cells [9^12]. In contrast, genetic al-
terations of p19INK4d gene are rare events in human tumors,
although alterations of p19INK4d gene in osteosarcoma, and a
loss of p19INK4d protein in testicular cancer have been re-
ported [32^34]. As a member of the INK4 family, p19INK4d
is known to possess a function similar to that of p16INK4a [8].
This functional similarity to p16INK4a suggests that p19INK4d
may function as a replacement for p16INK4a in case p16INK4a is
inactivated. Therefore transcriptionally regulated agents of
p19INK4d gene may contribute to new strategies for the pre-
vention or therapy of malignancies which we have termed
‘gene-regulating chemoprevention or chemotherapy’ [35,36].
Our study of the human p19INK4d promoter may provide in-
formation useful for these strategies.
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